EYP-2301

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals is strategically focused on developing and commercializing innovative, sustained-release therapeutics to address the high treatment burden in serious retinal diseases. Its lead candidate, DURAVYU™ (EYP-1901), a vorolanib-loaded insert, is advancing through pivotal Phase 3 trials for wet AMD and diabetic macular edema (DME), with key data readouts expected in 2026. The company leverages its proprietary, clinically validated Durasert E™ bioerodible delivery platform to create durable treatments that aim to improve patient outcomes and compliance while capturing significant market opportunity.

Therapeutic Areas